Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies

人类强效中和抗体二价结合并抑制 SARS-CoV-2 感染的结构基础

阅读:4
作者:Renhong Yan #, Ruoke Wang #, Bin Ju #, Jinfang Yu #, Yuanyuan Zhang #, Nan Liu #, Jia Wang, Qi Zhang, Peng Chen, Bing Zhou, Yaning Li, Yaping Shen, Shuyuan Zhang, Long Tian, Yingying Guo, Lu Xia, Xinyue Zhong, Lin Cheng, Xiangyang Ge, Juanjuan Zhao, Hong-Wei Wang, Xinquan Wang, Zheng Zhang, Linqi Zh

Abstract

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against coronavirus disease 2019 (COVID-19). We isolated a large number of nAbs from SARS-CoV-2-infected individuals capable of disrupting proper interaction between the receptor binding domain (RBD) of the viral spike (S) protein and the receptor angiotensin converting enzyme 2 (ACE2). However, the structural basis for their potent neutralizing activity remains unclear. Here, we report cryo-EM structures of the ten most potent nAbs in their native full-length IgG-form or in both IgG-form and Fab-form bound to the trimeric S protein of SARS-CoV-2. The bivalent binding of the full-length IgG is found to associate with more RBDs in the "up" conformation than the monovalent binding of Fab, perhaps contributing to the enhanced neutralizing activity of IgG and triggering more shedding of the S1 subunit from the S protein. Comparison of a large number of nAbs identified common and unique structural features associated with their potent neutralizing activities. This work provides a structural basis for further understanding the mechanism of nAbs, especially through revealing the bivalent binding and its correlation with more potent neutralization and the shedding of S1 subunit.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。